Gynecologic Cancers Market Analysis and Reports | UK Conference Series

Market Analysis - Gynecologic Cancers 2017


Gynecologic Cancer is the field of medicine that focuses on cancers of the female generative system. As experts they have wide training in the diagnosis and treatment of this cancer.

In 2012, there were about 4.7 million cases of women cancer worldwide in which 54% cases arose in less developed countries. Although the occurrence and mortality from Gynecologic cancer are major, other cancers are very uncommon.

Gynecologic Cancers Statistics

In the world about 350,000 women are identified with Gynecologic Cancer each year. In 2013, an expected 91,730 were diagnosed. An estimated 170,000 new cases of Gynecologic Cancer were expected to be diagnosed in 2016 in the Europe, and over 70,000 females will lose their battle with this deadly disease. In addition to imposing a significant load on patients and their relations, Gynecologic Cancer places a major burden on the health care organization. Every woman is at risk for emerging a Gynecologic Cancer. It is expected that there will be about 200,000 new cases diagnosed and around 90,000 deaths from Gynecologic Cancer in the UK during 2017.

Scope and Importance of Gynecologic Cancer Research

Gynecologic Cancer is the third most commonly diagnosed cancer and the leading cause of cancer death in females’ worldwide, accounting for 9% (529,800) of the total new cancer cases and 8% (275,100) of the total cancer deaths among females. More than 85% of these cases and deaths occur in developing countries.

Early detection of tumour biology and treatment of Gynecologic Cancer in younger women is more as compared to older women. Effort was devoted to the type of problems met in conducting the analyses and, where data were inadequate, recommending research guidelines or approaches.

Physicians are also involved in leading-edge programs in the prevention of cervical and Gynecologic Cancer through regular screenings and the identification of precancerous cervical lesions associated with papilloma virus infections.Organized screening procedures can support to detect Gynecologic Cancer

A pap smear can identify Gynecologic Cancer. It is suggested to begin analysis every three years early at age 21.

1. A pelvic exam images the rectum, vagina, cervix, fallopian tubes, uterus, ovaries, and Pelvic tests should be done annually, beginning at 21 and can help detect irregularities of the female reproductive system.

2. An endometrial tissue sample checks for abnormal cells or signs of uterine cancer which can be done for women with a high risk for endometrial cancer due to an inborn susceptibility or when there are symptoms that need to be evaluated.

Members Associated Gynecologic Cancer Research

Gynecologic Cancer research associated members in UK are about 100000, in Europe about 350000 members and worldwide about 550000 research members. Major Gynecologic Cancer associated hospitals in UK are around 5% when compared to worldwide.


Hospitals in UK

  •  The London Clinic
  •   Teenage Cancer Trust
  •   St Thomas' Hospital
  •   London Bridge Digestion Clinic
  •   Macmillan Cancer Support
  •   NHS Trust Hospital

Hospitals in Europe

  •         Johns Hopkins Hospitals
  •         European Competence Center for Ovarian Cancer
  •         European institute of oncology
  •         University Medical Center Freiburg
  •         Institute Gustave Roussy, Europe
  •         Interdisciplinary Intestinal Tumor Center
  •         University Hospitals of Geneva
  •         Royal Berkshire NHS Foundation Trust
  •         Guy's and St Thomas' Hospital NHS
  •         University Hospital Dusseldorf
  •         NHS Fife

Hospitals worldwide

  •         Georgetown Lombardi Comprehensive Cancer Center Northwest, Washington
  •         Institute Gustave Roussy Villejuif, France
  •         M.D. Anderson Cancer Center, United States
  •         Dana Cancer Center
  •         Abramson Cancer Center Philadelphia, United States
  •         Nuffield Health Bristol Hospital, UK
  •         St. James’ Institute of Oncology, UK
  •         Mercy San Juan Medical Center, California
  •         Fortis Memorial Research Institute, India
  •         El Camino Hospital, California
  •         Johns Hopkins Hospital

Societies and associations Associated with Gynecologic Cancer Research

In world there are about 9,685 societies which are specifically associated with Gynecologic Cancer, in which 1289 societies are from Europe and the remaining 269 societies are from London.

Association in UK

  •     Jo’s Cervical Cancer Trust Forum
  •      Macmillan Cancer Support
  •      National Cancer Institute
  •      British Gynaecological Cancer Society
  •      Cancer Research UK
  •      UK Oncology Nursing Society
  •      The British Society for Gynaecological Endoscopy
  •      British Undergraduate Society of Obstetrics and Gynaecology                

  Association in Europe

  •        British Gynaecological Cancer Societies
  •        European Society of Gynaecological Oncology
  •        International Gynecologic Cancer Society
  •        European Network of Gynaecological Oncological Trial groups
  •        Italian Society of Gynecology and Obstetrics
  •        Europe European Network of Cancer Registries
  •        Europe European Oncology Nursing Society EONS
  •        Gynecological Cancer Group
  •         Europe European Breast Cancer Coalition
  •         EORTC Gynecologic Oncology            
  •         The European Consortium for Cervical Cancer Education

Association in Worldwide

  •         American Gynaecological & Obstetrical Society
  •         International Society of Ultrasound in Obstetrics and Gynecology
  •         Nordic Federation of Societies of Obstetrics and Gynecology
  •         International Society of Psychosomatic Obstetrics and Gynaecology
  •         New York Gynecological Society
  •         The international Society of Gynecology and Endoscopy
  •         Breast Cancer Society of Canada
  •         American Cancer Society
  •         Association of Cancer Physicians
  •         Association of Oncology Social Work
  •         Australian Cervical Cancer Foundation

Universities Associated with Gynecologic Cancer Research

Universities in UK

  •         Imperial College London
  •         University College London
  •         King’s College London
  •         Queen Mary University of London
  •         Manchester University
  •         University of Glasgow
  •         Imperial College London
  •         University of Birmingham
  •         Kingston University London
  •         University of Cambridge
  •         Institute of Cancer Research
  •         Birkbeck, University of London

 Universities in Europe

  •           University of Cambridge
  •           University of Edinburgh
  •           University of Manchester
  •           University of Oxford
  •           Heidelberg University
  •           University of Amsterdam
  •           Swiss Federal Institute of Technology Zurich
  •           Wageningen University and Research Center
  •           University of Bristol
  •           Aarhus University
  •           University of Copenhagen

Universities in Worldwide

  •            Harvard University
  •            University of Cambridge
  •            Massachusetts Institute of Technology
  •            Johns Hopkins University
  •            Stanford University
  •            University of California, San Francisco
  •            Yale University
  •            University of California, Los Angeles
  •            Texas A & M University
  •            Princeton University
  •            Cornell University
  •            Emory University
  •            Stanford University


Industries Associated with Gynecologic Cancers Research

Industries associated with Gynecologic Cancer over all the world is about 80% in which 14% of industries are in UK and in London about 6%.

  •         Johnson & Johnson
  •         Novartis
  •         Roche
  •         Pfizer
  •         Sanofi
  •         Merck
  •         Bristol-myers squibb
  •         Eli Lilly
  •         Celgene
  •         Takeda
  •         AstraZeneca
  •         Merck & Co.
  •         Bayer
  •         Amgen Celgene
  •         Otsuka
  •         Pharmacyclics
  •         Incyte

Market Value on Gynecologic Cancer Research

The global Gynecologic Cancer market in 2010 was valued at $54bn, an increase of 5.1% over the previous year‘s sales of $51.3bn, and is forecasted to grow at a CAGR of 6.9% from 2010–16, reaching $81bn in 2016.

·      Collectively, the seven major markets (US, 5EU, and Japan) represented 79.1% (or $43bn) of in the global cancer market in 2010. In terms of size, the US dominated the global cancer market, with 2010 sales of $21bn and a market share of 38.5%.

·      The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. Collectively, the leading 10 brands accounted for almost 58.2% (or $31.4bn) of the global cancer market in 2010.

·      In 2010 antineoplastics was the leading drug class in the global cancer market. The global antineoplastic market was valued at $46bn in 2010 at a year-on-year (Y-o-Y) growth of 7.3%. The major drugs that contributed to the 2010 sales in the antineoplastic category were Roche‘s Avastin (bevacizumab) at $6.2bn, Herceptin (trastuzumab) at $5.2bn, and MabThera (rituximab) at $5.1bn, with Y-o-Y sales growth of 3.8%, 3.1%, and 3.3% respectively.

·      The cytostatic hormonal market registered 2010 sales of $8bn at a Y-o-Y decline of 6.5%. AstraZeneca‘s Arimidex (anastrozole) and Novartis‘s Femara (letrozole) led this class, reaching sales of $1.5bn and $1.3bn respectively in 2010.


Market Growth of Gynecologic Cancer Research in the last and upcoming ten years

Tech Navio's analysts forecast the Global Gynecologic Cancer market to grow at a CAGR of 12.47% over the period 2013-2018. One of the key factors contributing to this market growth is the increase in prevalence of Gynecologic Cancer. The Global Gynecologic Cancer market has also been witnessing the emergence of personalized medicines. However, the increase in use of CAM could pose a challenge to the growth of this market. In next ten years as population ages, the number of people diagnosed with cancer is expected to be double. The volume of cancer services continues to grow. Radiation therapy by 3%,infusion therapy by 7%;Gynecologic services by 10%(annually).With earlier detection, cancer patients will be identified earlier with improvements in chemotherapy, patients will be able to tolerate more treatments, all of which will result in more treatments per patient and more lives saved.

Products manufactured by the industry related Gynecologic

Cancer Research

Market Value:

·    Neosar (Cyclophosphamide)- manufactured by Roxane Laboratories Inc and the market value is 17.06$               

·    Paraplat (Carboplatin)-manufactured by Bristol-Myers Squibb Company and the market  value is128$                    

· Platinol (Cisplatin)-manufactured by Bristol-Myers Squibb Company and the market value    is15.3$·               

 Gemzar (Gemcitabine Hydrochloride)-manufactured by Eli Lilly and Company and the market value is 26.1$           

·  Clafen (Cyclophosphamide)-manufactured by Selleckchem and the market value is150$

2nd International Congress on Contemporary Issues in Women Cancers and Gynecologic Oncology

Dates: August 28-29, 2017

Venue: London, UK

Theme: An initiative to overcome the contemporary issues of women cancer


Target Audience

  •          Oncologists
  •          Gynaecologists
  •          Radiologists
  •          Pathologists
  •          Scientists
  •          Students
  •          Researchers
  •          Faculty
  •          Nurses
  •          Gynecology Cancer Associations and Societies
  •          Business Entrepreneurs
  •          Training Institutes
  •          Pharmaceutical Companies
  •          Medical Devices Companies
  •          Data Management Companies